MICROPORT CARDIO.MEDTECH. (72X) - Total Liabilities
Based on the latest financial reports, MICROPORT CARDIO.MEDTECH. (72X) has total liabilities worth €450.55 Million EUR (≈ $526.74 Million USD) as of June 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
MICROPORT CARDIO.MEDTECH. - Total Liabilities Trend (2021–2024)
This chart illustrates how MICROPORT CARDIO.MEDTECH.'s total liabilities have evolved over time, based on quarterly financial data. See MICROPORT CARDIO.MEDTECH. working capital to net assets to evaluate short-term liquidity relative to the company's equity base.
MICROPORT CARDIO.MEDTECH. Competitors by Total Liabilities
The table below lists competitors of MICROPORT CARDIO.MEDTECH. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Synergy Innovation Co. Ltd
KQ:048870
|
Korea | ₩67.50 Billion |
|
Ultralife Corporation
NASDAQ:ULBI
|
USA | $90.89 Million |
|
Calitech Co Ltd
TWO:6532
|
Taiwan | NT$294.20 Million |
|
Aspen Group Ltd
TA:ASGR
|
Israel | ILA2.68 Billion |
|
Kewaunee Scientific Corporation
NASDAQ:KEQU
|
USA | $117.36 Million |
|
Arrow Exploration Corp
V:AXL
|
Canada | CA$50.96 Million |
|
Trivago NV
NASDAQ:TRVG
|
USA | $145.15 Million |
|
Brisbane Broncos Ltd
AU:BBL
|
Australia | AU$21.96 Million |
Liability Composition Analysis (2021–2024)
This chart breaks down MICROPORT CARDIO.MEDTECH.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see MICROPORT CARDIO.MEDTECH. market cap and net worth.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 6.94 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.21 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.17 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how MICROPORT CARDIO.MEDTECH.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for MICROPORT CARDIO.MEDTECH. (2021–2024)
The table below shows the annual total liabilities of MICROPORT CARDIO.MEDTECH. from 2021 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | €454.07 Million ≈ $530.86 Million |
+87.44% |
| 2023-12-31 | €242.25 Million ≈ $283.21 Million |
-2.14% |
| 2022-12-31 | €247.55 Million ≈ $289.41 Million |
-6.77% |
| 2021-12-31 | €265.52 Million ≈ $310.42 Million |
-- |
About MICROPORT CARDIO.MEDTECH.
MicroPort CardioFlow Medtech Corporation, a medical device company, engages in the research, development, and commercialization of transcatheter and surgical solutions for structural heart diseases in the People's Republic of China and internationally. The company engages in research and development, manufacture, and sale of medical devices in the field of left atrial appendage, and treating valv… Read more